Q-omics provides the consensus-scored FOXO3B profile across patient tissues and cancer cell-line models. FOXO3B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FOXO3B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, FOXO3B RNA expression shows 20,134 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where FOXO3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXO3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXO3B survival associations across molecular data types. FOXO3B RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXO3B RNA expression–survival associations across cancer types. High FOXO3B expression shows unfavorable associations in BLCA, MESO and LIHC, but favorable associations in KIRC, UCS and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FOXO3B RNA expression.
This table summarizes FOXO3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FOXO3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXO3B shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in HNSC, LUSC and LIHC. The HNSC box plot shows higher FOXO3B RNA expression in tumor versus normal tissue (log2 FC = +0.612, t-test p < 0.001).
This table shows molecular features associated with FOXO3B in patient tissues and cancer cell lines. In patient samples, FOXO3B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXO3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS.
